Part VII — Synthesis and Reference
Chapters 37–40
Thirty-six chapters ago, this book made a promise: that you would finish able to evaluate any peptide claim you encounter — including ones about molecules that did not exist when it was written.
Part VII is where that promise gets tested.
Four chapters, four jobs
Chapter 37 — The Peptide Evidence Table collects every rating in the book into one place. Roughly seventy peptide-claim pairs, sorted by tier, each with its mechanism, its approval status, its key evidence, its risks, and the specific finding that would move it.
But the table is not the chapter's real content. The patterns are. Read the ✅ column top to bottom and something becomes visible: the peptides with strong evidence overwhelmingly replace a missing hormone, block an overactive receptor, or deliver a payload to a specific address. Read the ❌ column and a different pattern appears: broad, systemic, "optimizing" claims about healthy people, supported by animal work, sold before they were tested.
That is not a coincidence and it is not a bias in the ratings. It reflects something real about which biological problems are tractable — and it gives you a genuinely useful prior for any new peptide you meet. Chapter 37 also does something few reference chapters do: it names the ratings that are contested, where reasonable experts would disagree, and says why.
Chapter 38 — Peptide Regulation is the machinery. What an approval actually certifies (less than most people assume, and about something more specific). The U.S. pathway from IND to Phase III to NDA. Why compounding law has a shortage clause and what happened when the shortage ended. The "research chemical" channel and how enforcement really works. WADA's Prohibited List and therapeutic use exemptions. The supplement-versus-drug category error that enables most peptide marketing. And, most usefully, how to check the current status of anything yourself — because every regulatory statement in this book is dated, and dates expire.
Chapter 39 — Talking to Your Doctor About Peptides is the chapter with the highest chance of changing a reader's life, and it is not about peptides at all. It is about a conversation that routinely goes badly in both directions: a patient who arrives with printouts and gets dismissed, a physician who has eleven minutes and no training in a field that did not exist during their residency. The chapter covers what your clinician actually knows, how to prepare a one-page brief, the five questions worth asking, why "not evidence-based" and "proven not to work" are completely different statements, and how to disclose something you are already taking without the conversation collapsing.
It also closes the book's longest-running thread — the Ozempic conversation. A friend asks whether they should take it. In Chapter 1 you could not answer. By Chapter 39 you can, and the answer is better than a yes or a no.
Chapter 40 — Your Peptide Evidence Dossier is the capstone. You assemble everything, audit your own entries against five specific failure modes, and then do the thing the whole book was built for: apply the method to a peptide invented after publication, and then to a claim that is not about peptides at all.
What the book concludes
Two sentences, and they are both true at once:
The peptide revolution is real. GLP-1 receptor agonists are among the most important drug discoveries of this century. More than eighty peptide medicines are in routine clinical use. Radioligand therapy delivers radiation to a tumor by molecular address. Personalized cancer vaccines are in human trials. This is a serious, productive, rapidly advancing field, and the molecules themselves are remarkable things.
And the hype is real. Most of the peptides that generate the most enthusiasm have no completed human trials. A great deal of what is sold is of unverified identity and purity. The most confident voices in the space are frequently the ones with something to sell, and the mechanism-sounds-plausible argument continues to persuade intelligent people who ought to know better.
Neither sentence cancels the other. Anyone who tells you the field is a miracle is wrong. Anyone who tells you it is a scam is also wrong. Holding both simultaneously — without collapsing into evangelism or contempt — is the entire skill, and it is much harder than it sounds.
What you take with you
The verdicts in this book will age. Some ❌ ratings will become ⚠️ or ✅ because somebody finally ran the trial. Some ⚠️ ratings will become ❌ because the larger study failed to replicate. New compounds will appear with new claims and the same five-stage hype cycle.
The method does not age.
What is the specific claim, for which population, on which endpoint? What evidence exists — and what rung of the ladder is it on? Who funded it? What would falsify it? What is the honest state of the unknown, and does the unknown matter more or less than the claimed benefit?
Those questions work on a peptide. They also work on a supplement, a device, a diet, a therapy, and a headline. That is the actual product of this book. The peptides were the curriculum. The judgment is what you keep.
📋 Your Evidence Dossier — Part VII
Chapter 37 asks you to compare every entry you wrote against the book's master table and find your drift — the places where you were more generous or more severe than the evidence warranted, and, more revealingly, whether you were consistently more generous about the compounds you wanted to work.
Everyone drifts. Noticing the direction of your own drift is the last skill the method has to teach, and it is the one that keeps working after you have forgotten every sequence in these pages.
Part VIII then does the only thing left to do with a finished method: it points it at claims about society rather than about molecules, and holds them to the same standard.